The potentially market-altering diabetes drug SRT501, developed by Sirtris pharmaceuticals, has been proven safe in its first phase clinical trials . Whether the drug is effective remains to be seen.
Speaking at the JP Morgan Health Care Conference, the MD of Sirtris Christoph Westphal made it clear that there were no safety issues. The drug, which is a reformulation of resveratrol, the red wine ingredient known for its health properties, has attracted considerable interest from investors .
The second half of this year will see phase 2 date being released, in which the efficiency of the drug will be tested. The drug, taken orally, could compete if it proven to react well with Metformin. Sirtris are clear that they have other, better drugs in their pipeline.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…